Izotropic Corp. (TSE:IZO)
:IZO
Want to see TSE:IZO full AI Analyst Report?
IZO Stock Chart & Stats
C$0.28
C$0.01(8.33%)
At close: 4:00 PM EST
C$0.28
C$0.01(8.33%)
Day’s Range― - ―
52-Week RangeC$0.19 - C$0.49
Previous CloseN/A
Volume236.24K
Average Volume (3M)43.33K
Market Cap
C$21.73M
Enterprise ValueC$24.50M
Total Cash (Recent Filing)C$364.08K
Total Debt (Recent Filing)C$3.14M
Price to Earnings (P/E)―
Beta-0.19
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding68,984,680
10 Day Avg. Volume24,438
30 Day Avg. Volume43,328
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-2.90
Price to Sales (P/S)0.00
P/FCF Ratio-22.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Product DifferentiationIzoview's core product is a dedicated breast CT system designed to improve screening, diagnosis and workflow versus conventional mammography. A focused, clinically differentiated device can create durable competitive advantage via clinical utility, workflow integration and IP if commercialized.
Improving Loss TrendsTTM net loss of about 2.5M marks a material improvement from prior multi‑million losses, signalling better cost discipline or R&D efficiency. Sustained reduction in operating losses can extend runway and raise the odds of reaching commercialization without immediate, large financing.
Moderated Cash BurnOperating and free cash flow are still negative (~-1.0M TTM) but materially improved versus prior years. A lower structural cash burn reduces near‑term refinancing pressure, providing management more time to finish development, pursue partnerships, or reach initial commercial milestones.
Bears Say
No Revenue / Pre‑commercialThe company reports no revenue and a negative gross profit, indicating its core product is not commercially generating sales. This structural lack of revenue forces dependence on external capital, leaves adoption unproven, and delays the path to sustained free cash flow and profitability.
Stressed Balance SheetNegative equity paired with material debt against a tiny asset base signals weakened solvency and limited financial flexibility. Structurally, this increases refinancing risk, constrains R&D and commercialization spending, and raises probability of dilutive financing or creditor-driven outcomes.
Persistent Funding NeedContinued negative operating cash flow (~-1.0M TTM) implies ongoing cash burn and explicit funding requirements absent revenue. Over a multi‑month horizon this forces capital raises or partnerships, which can dilute shareholders, alter strategic control, or delay product commercialization.
Izotropic News
IZO FAQ
What was Izotropic Corp.’s price range in the past 12 months?
Izotropic Corp. lowest stock price was C$0.19 and its highest was C$0.49 in the past 12 months.
What is Izotropic Corp.’s market cap?
Izotropic Corp.’s market cap is C$21.73M.
When is Izotropic Corp.’s upcoming earnings report date?
Izotropic Corp.’s upcoming earnings report date is Aug 21, 2026 which is in 112 days.
How were Izotropic Corp.’s earnings last quarter?
Izotropic Corp. released its earnings results on Mar 27, 2026. The company reported -C$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.004.
Is Izotropic Corp. overvalued?
According to Wall Street analysts Izotropic Corp.’s price is currently Overvalued.
Does Izotropic Corp. pay dividends?
Izotropic Corp. does not currently pay dividends.
What is Izotropic Corp.’s EPS estimate?
Izotropic Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Izotropic Corp. have?
Izotropic Corp. has 68,984,680 shares outstanding.
What happened to Izotropic Corp.’s price movement after its last earnings report?
Izotropic Corp. reported an EPS of -C$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.174%.
Which hedge fund is a major shareholder of Izotropic Corp.?
Currently, no hedge funds are holding shares in TSE:IZO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Izotropic Corp.
Izotropic Corporation, a MedTech company, commercializes diagnostic products for breast cancer. It develops and commercializes breast CT Imaging system; and 3D CT breast imaging platform for the earlier detection and diagnosis of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.
Technical Analysis
Spectral Medical
―
BioMark Diagnostics
―
Perimeter Medical Imaging AI
―
Sona Nanotech Inc
―
VentriPoint Diagnostics
―
Options Prices
Currently, No data available
---